Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan; Division of Nephrology, Department of Internal Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan; Committee of Renal Data Registry, the Japanese Society for Dialysis Therapy, Tokyo, Japan.
Committee of Renal Data Registry, the Japanese Society for Dialysis Therapy, Tokyo, Japan; Fujita Health University, Toyoake, Japan.
Am J Kidney Dis. 2015 Jun;65(6):899-904. doi: 10.1053/j.ajkd.2014.12.009. Epub 2015 Jan 30.
The quality of dialysis fluid water might play an important role in hemodialysis patient outcomes. Although targeted endotoxin levels of dialysis fluid vary among countries, evidence of the contribution of these levels to mortality in hemodialysis patients is lacking.
Retrospective cohort study using data from the Japan Renal Data Registry, a nationwide annual survey.
SETTING & PARTICIPANTS: 130,781 patients receiving thrice-weekly in-center hemodialysis for more than 6 months were enrolled at 2,746 facilities in Japan at the end of 2006. None of the patients changed facility or treatment modality during 2007.
Highest endotoxin level in dialysis fluid reported by each facility during 2006. Patients were categorized by facility endotoxin level into the following groups: <0.001, 0.001 to <0.01, 0.01 to <0.05, 0.05 to <0.1, and ≥0.1EU/mL. Age, sex, dialysis vintage, diabetes mellitus as a primary cause of end-stage renal disease, Kt/V, normalized protein catabolic rate, dialysis session duration, serum albumin, and hemoglobin were measured as potential confounders.
All-cause mortality, censored by transplantation; withdrawal from dialysis treatment; or end of follow-up.
Of 130,781 hemodialysis patients, 91.2% had facility endotoxin levels below the limit set for dialysis fluid in Japan (<0.05EU/mL). During a 1-year follow-up, 8,978 (6.9%) patients died of all causes. The rate of all-cause mortality at 1 year was highest in the ≥0.1-EU/mL category (88.0 deaths/1,000 person-years). Patients in the ≥0.1-EU/mL group exhibited an increased risk of all-cause mortality of 28% (95% CI, 10%-48%) compared to the <0.001-EU/mL group.
Endotoxin level in dialysis fluid is reported as categorical data. No information about variation in endotoxin levels in dialysis fluid over time.
Higher facility endotoxin levels in dialysis fluid may be related to increased risk for all-cause mortality among hemodialysis patients. Correcting this modifiable facility water management practice might improve the outcome of hemodialysis patients.
透析液水的质量可能在血液透析患者的预后中发挥重要作用。尽管各国对透析液内毒素的目标水平存在差异,但缺乏这些水平对血液透析患者死亡率影响的证据。
使用来自日本肾脏数据登记处的回顾性队列研究,这是一项全国性年度调查。
2006 年底,在日本的 2746 家机构中,招募了 130781 名接受每周三次中心血液透析治疗超过 6 个月的患者。在 2007 年期间,没有患者改变机构或治疗方式。
每个机构在 2006 年报告的透析液中最高内毒素水平。患者根据机构内毒素水平分为以下几组:<0.001、0.001-<0.01、0.01-<0.05、0.05-<0.1 和≥0.1EU/mL。年龄、性别、透析年限、糖尿病作为终末期肾病的主要病因、Kt/V、标准化蛋白分解率、透析时间、血清白蛋白和血红蛋白被测量为潜在的混杂因素。
在 130781 名血液透析患者中,91.2%的患者的机构内毒素水平低于日本规定的透析液限值(<0.05EU/mL)。在 1 年的随访期间,8978 名(6.9%)患者死于各种原因。在≥0.1-EU/mL 组中,1 年内全因死亡率最高(88.0 例/1000 人年)。与<0.001-EU/mL 组相比,≥0.1-EU/mL 组全因死亡率的风险增加了 28%(95%CI,10%-48%)。
透析液中的内毒素水平被报告为分类数据。没有关于透析液中内毒素水平随时间变化的信息。
透析液中较高的机构内毒素水平可能与血液透析患者全因死亡率增加有关。纠正这种可修正的设施用水管理实践可能会改善血液透析患者的预后。